Allelix Biopharmaceuticals Inc. said Friday that it will supplyDaewoong Pharmaceutical Co. Ltd. of Seoul, South Korea, withgenetically engineered epidermal growth factor for Daewoongto incorporate into pharmaceutical products.

Under the agreement, Allelix (TSE:AXB) of Mississauga, Ontario,will supply EGF to Daewoong for formulation andmarketing in Korea and other Asian markets.

EGF is a naturally occurring protein that stimulates the growthof many cell types, particularly epidermal cells such as skin.The protein has potential uses in ophthalmic and tissue repairapplications.

(c) 1997 American Health Consultants. All rights reserved.